GT BIOPHARMA, INC. Preferred Stock Dividends, Income Statement Impact
GT BIOPHARMA, INC. (GTBP) reported Preferred Stock Dividends, Income Statement Impact of $433.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-08-14
- GT BIOPHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- GT BIOPHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2026-03-31 was $433.00K.
- GT BIOPHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2025-09-30 was $144.00K.
- GT BIOPHARMA, INC. preferred stock dividends, income statement impact for the quarter ending 2025-06-30 was $85.00K.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month |
|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $433.00K 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $433.00K 10-Q · filed 2026-05-15 | ||
| 2025-09-30 | $144.00K 10-Q/A · filed 2026-03-06 | $229.00K derived: sum of 2 quarters · filed 2026-03-06 | $229.00K 10-Q/A · filed 2026-03-06 |
| 2025-06-30 | $85.00K 10-Q/A · filed 2026-03-06 | $85.00K 10-Q/A · filed 2026-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |